Structure Therapeutics In...
26.77
1.39 (5.48%)
At close: Jan 15, 2025, 1:56 PM

Structure Therapeutics Statistics

Share Statistics

Structure Therapeutics has 57.25M shares outstanding. The number of shares has increased by 23.37% in one year.

Shares Outstanding 57.25M
Shares Change (YoY) n/a
Shares Change (QoQ) 3.79%
Owned by Institutions (%) n/a
Shares Floating 54.18M
Failed to Deliver (FTD) Shares 24.83K
FTD / Avg. Volume 2.96%

Short Selling Information

The latest short interest is 10.44M, so 18.24% of the outstanding shares have been sold short.

Short Interest 10.44M
Short % of Shares Out 18.24%
Short % of Float 19.28%
Short Ratio (days to cover) 15.69

Valuation Ratios

The PE ratio is -16.71 and the forward PE ratio is -48.01.

PE Ratio -16.71
Forward PE -48.01
PS Ratio 0
Forward PS null
PB Ratio 3.31
P/FCF Ratio -18.34
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Structure Therapeutics Inc..

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 19.14, with a Debt / Equity ratio of 0.

Current Ratio 19.14
Quick Ratio 19.14
Debt / Equity 0
Total Debt / Capitalization 0
Cash Flow / Debt 0
Interest Coverage -7.67

Financial Efficiency

Return on equity (ROE) is -0.2% and return on capital (ROIC) is -22.48%.

Return on Equity (ROE) -0.2%
Return on Assets (ROA) -0.19%
Return on Capital (ROIC) -22.48%
Revenue Per Employee 0
Profits Per Employee -658.97K
Employee Count 136
Asset Turnover 0
Inventory Turnover 0

Taxes

Income Tax 236.00K
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by -43.48% in the last 52 weeks. The beta is -5.13, so Structure Therapeutics 's price volatility has been lower than the market average.

Beta -5.13
52-Week Price Change -43.48%
50-Day Moving Average 32.36
200-Day Moving Average 37.94
Relative Strength Index (RSI) 34.13
Average Volume (20 Days) 838.43K

Income Statement

Revenue n/a
Gross Profit -949.17K
Operating Income -102.78M
Net Income -89.62M
EBITDA -102.46M
EBIT n/a
Earnings Per Share (EPS) -2.44
Full Income Statement

Balance Sheet

The company has 129.79M in cash and 5.45M in debt, giving a net cash position of 124.34M.

Cash & Cash Equivalents 129.79M
Total Debt 5.45M
Net Cash 124.34M
Retained Earnings -206.57M
Total Assets 933.22M
Working Capital 890.22M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -79.49M and capital expenditures -2.17M, giving a free cash flow of -81.66M.

Operating Cash Flow -79.49M
Capital Expenditures -2.17M
Free Cash Flow -81.66M
FCF Per Share -2.22
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

GPCR does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -9.63%
FCF Yield -5.63%
Dividend Details

Analyst Forecast

The average price target for GPCR is $80, which is 215.7% higher than the current price. The consensus rating is "Buy".

Price Target $80
Price Target Difference 215.7%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Scores

Altman Z-Score 26.14
Piotroski F-Score 3